A decrease in serum sialyltransferase levels in Alzheimer's disease.
A reliable antemortem serum marker for Alzheimer's disease (AD) would be of great importance for the early detection and subsequent therapeutic management of the disease. We have noted a significant decrease in serum levels of the soluble form of the sialyltransferase enzyme in a group of AD patients when compared with both age-matched elderly (over 60 years) and young (under 60 years) controls. In a population of Down's syndrome patients, who develop AD pathology with increasing age, there was an age-related decrease in serum sialyltransferase activity in patients from 20 to 60 years to approach enzyme levels similar to those observed in the AD group. This significant decrease in serum sialyltransferase levels observed may both prove a useful peripheral early biochemical marker of neurodegeneration and provide an indication of the underlying cellular events that occur during the process of nerve cell death in AD.
Maguire
T M
TM
Department of Pharmacology, University College, Dublin, Ireland.
Gillian
A M
AM
O'Mahony
D
D
Coughlan
C M
CM
Dennihan
A
A
Breen
K C
KC
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000375:Aging / Q000378:metabolism; D000544:Alzheimer Disease / Q000097:blood / Q000201:enzymology*; D015415:Biomarkers; D004314:Down Syndrome / Q000097:blood / Q000201:enzymology; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D012799:Sialyltransferases / Q000097:blood*
D015415:Biomarkers; D012799:Sialyltransferases